Seroimmunological monitoring of Campylobacter pylori in patients with cystic fibrosis

Przyklenk, B.; Bauernfeind, A.; Bornschein, W; Bertele, R M; Harms, Karsten; Arleth, S.

doi:10.1016/0888-0786(89)90038-3

Cited by 9 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete absorption was found when the C. jejuni pool was absorbed with P. aeruginosa antigens (lane 3b). Absorption with C. jejuni antigens also revealed complete absorption of all four small-molecular-size bands, of 36,35,30, and 14 kDa (lane 3c), indicating a cross-reaction.…”

Section: Resultsmentioning

confidence: 96%

“…Furthermore, the polyclonal rabbit antibodies to P. aeruginosa 60-kDa GroEL common protein antigen revealed several bands against H. pylori and P. aeruginosa at about 14, 27 to 30, 47 to 50, and 60 kDa, indicating corresponding cross-reactions between H. pylori and P. aeruginosa and maybe also the presence of cross-reactive antibodies from Bordetella bronchisepticum, which frequently infects rabbits (19). According to these results, the GroEL protein of P. aeruginosa and H. pylori is responsible for part of the cross-reacting antibodies which may give rise to false-positive antibody titers to H. pylori in CF patients (36).…”

Section: Discussionmentioning

confidence: 92%

“…Patients with CF may suffer from gastrointestinal problems which are often associated with exocrine pancreatic dysfunction (22), but few studies have, until now, focused on the possibility of H. pylori being involved in the pathogenesis. Przyklenk et al (36) presented evidence that gastritis due to H. pylori was not more common in CF patients than in non-CF controls. However, significantly elevated IgG titers were detected in two age groups, i.e., in children less than 12 months of age and in adults between 20 and 24 years of age.…”

Section: Discussionmentioning

confidence: 99%

“…The immunoglobulin G (IgG) antibody level to H. pylori increases in 10 to 15% of normal asymptomatic children with increasing age (3). The prevalence of antibodies to H. pylori in patients with CF was compared with that in non-CF controls by Przyklenk et al (36), who found that the seroprevalence of H. pylori was the same for both groups (36). In contrast to this, Littlewood (28) suggested an increased prevalence of H. pylori in CF patients and proposed that this infection should be excluded in patients with persisting upper gastrointestinal symptoms.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori

Johansen

Nørgaard

Andersen

et al. 1995

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

Cystic fibrosis (CF) patients suffer from many of the gastrointestinal conditions which occur in non-CF individuals, e.g., dyspepsia and peptic ulceration. These symptoms may be caused by Helicobacter pylori but could also be due to either pancreatic insufficiency or the intensive antibiotic treatment used in CF patients. Since CF patients chronically infected with Pseudomonas aeruginosa produce antibodies against a wide range of antigens, including antigens common to many other bacteria, e.g., GroEL and lipopolysaccharide, we studied, by the Western blot (immunoblot) technique, the specificity of immunoglobulin G antibodies to H. pylori in Danish CF patients chronically infected with P. aeruginosa, CF patients without P. aeruginosa infection but with Haemophilus influenzae infection, patients with dyspeptic ulcers associated with H. pylori, and patients recovering from acute Campylobacter jejuni or Campylobacter coli infection. Sera from CF patients with chronic P. aeruginosa or H. influenzae infection and patients recovering from acute C. jejuni infection cross-reacted with H. pylori antigens. A strong cross-reacting protein antigen at approximately 14 kDa and minor cross-reactive antigens at approximately 27, 30, and 60 kDa (the heat shock protein GroEL is equivalent to the common antigen of P. aeruginosa) could be demonstrated. The results of this study show that high immunoglobulin G antibody titers against H. pylori in CF patients cannot be regarded as indicating present or past H. pylori infection unless their specificity is proven by absorption studies.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori

Johansen

Nørgaard

Andersen

et al. 1995

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

show abstract

“…The role of H. pylori in gastroduodenal disease in the CF population remains largely unknown. The overall seroprevalence of H. pylori in patients with CF has been described in earlier studies as being similar to that in non-CF control subjects [5]. In contrast, a more recent study suggests that there is an increased prevalence of H. pylori in the CF population [3].…”

mentioning

confidence: 89%

Helicobacter pylori and Clostridium difficile in Cystic Fibrosis Patients

et al. 2006

View full text Add to dashboard Cite

We describe the prevalence of H. pylori and toxigenic Clostridium difficile (CD) infection and its relationship with gastrointestinal symptoms and pancreatic sufficiency (PS) or insufficiency (PI) in cystic fibrosis (CF) patients. Stool specimens from 30 consecutive patients with CF, aged 1-44, and from 30 healthy similarly aged subjects were tested for the H. pylori antigen by specific monoclonal antibodies and for CD toxins by Tox A/B assay and Tox A assay. CF patients were assessed clinically and tested for specific H. pylori serum antibodies and for mutations. In CF patients, the prevalence of H. pylori antigen was 16.6% (5/30), compared to 30% (9/30) in controls. Of the 26 CF patients with PI, only 2 (7.6%) were infected by H. pylori, compared with 3 of the 4 (75%) patients with PS (P=0.001). H. pylori infection was diagnosed in 3 of 5 (60%) CF patients carrying mild mutations, compared to 1 of 25 (4%) CF patients carrying severe mutations (P=0.01). Fourteen of 30 (46.6%) stool specimens from CF patients tested positive in the ToxA/B assay, and 3 of 14 tested positive for ToxA. No significant differences in antibiotic use, severity of lung disease, PI, chronic abdominal pain, or genotype were found between the two groups. None of the controls was positive for CD toxins. Prevalence of H. pylori infection in CF patients was lower than in similarly aged non-CF controls. CF patients with PI or a history of distal intestinal obstruction syndrome and those carrying mutations associated with a severe phenotype were protected against H. pylori infection. Almost half of the CF patients were asymptomatic carriers of CD producing mostly toxin B. More studies are needed to confirm our results in a larger group of CF patients.

show abstract

Seroprevalence of Helicobacter pylori Infection in Cystic Fibrosis and Its Cross‐Reactivity With Anti‐Pseudomonas Antibodies

Israel,

Khanna,

Cutler

et al. 2000

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Background:The prevalence of Helicobacter pylori infection and its role in gastroduodenal disease in cystic fibrosis (CF) are controversial. Additionally, serologic determination of infection in this population may be inaccurate because of cross‐reactivity with other bacterial species. The seroprevalence of H. pylori in a cohort of patients with CF and its cross‐reactivity with Pseudomonas antibodies were investigated.Methods:A research enzyme‐linked immunosorbent assay (ELISA), and three commercial serologic assays (PyloriStat; BioWhittaker, Walkersville, MD, U.S.A.; Flexsure; SmithKline Diagnostics, Inc., San Jose, CA, U.S.A.; and HM‐CAP; EPI, Stony Brook, NY, U.S.A.) at three independent laboratories determined the seroprevalence of anti‐H. pylori IgG antibodies in 70 patients with CF. Cross‐reactivity between solid‐phase H. pylori antigens and Pseudomonas antibodies was ascertained by a competitive inhibition assay, preadsorbing sera of patients with CF with whole cell proteins from different Pseudomonas species, and serum reanalysis by each assay. Western blot analysis before and after adsorption was performed to identify potential cross‐reactive antigens.Results:The research ELISA, Flexsure, Pyloristat, and HM‐CAP initially showed H. pylori seropositivity of 47%, 28%, 24%, and 37%, respectively. Postadsorption seropositivity declined to 8%, 0%, 0%, and 15%, respectively. All patients with research ELISA true‐positive results were confirmed endoscopically to have H. pylori infection. Western blot analysis showed a 31‐kDa H. pylori protein with antigenic epitopes common to both bacterial species.Conclusions:Cross‐reactivity between solid‐phase H. pylori antigens and anti‐Pseudomonas antibodies occurs in patients with CF. A high index of suspicion should be assumed in evaluating results of serologic H. pylori tests in this population. Preadsorption of CF sera with Pseudomonas proteins should be used in serologic testing.

show abstract

Seroimmunological monitoring of Campylobacter pylori in patients with cystic fibrosis

Cited by 9 publications

References 23 publications

Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori

Cross-reactive antigens shared by Pseudomonas aeruginosa, Helicobacter pylori, Campylobacter jejuni, and Haemophilus influenzae may cause false-positive titers of antibody to H. pylori

Helicobacter pylori and Clostridium difficile in Cystic Fibrosis Patients

Seroprevalence of Helicobacter pylori Infection in Cystic Fibrosis and Its Cross‐Reactivity With Anti‐Pseudomonas Antibodies

Contact Info

Product

Resources

About